Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.88 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.70 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | PARP1 | P09874 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzophenone SCHEMBL27436227 | 0.94 | ALDH1A1 (0.88) | ALDH1A1TDP1L3MBTL1SRD5A2ATM | |
| Benzophenone SCHEMBL17745 | 0.94 | ALDH1A1 (1.00) | ALDH1A1TDP1L3MBTL1SRD5A2ATM | |
| Benzophenone SCHEMBL28180817 | 0.94 | ALDH1A1 (1.00) | ALDH1A1TDP1L3MBTL1SRD5A2ATM | |
| Benzophenone SCHEMBL1074283 | 0.94 | ALDH1A1 (1.00) | ALDH1A1TDP1L3MBTL1SRD5A2ATM | |
| Benzophenone SCHEMBL30537001 | 0.94 | ALDH1A1 (1.00) | ALDH1A1TDP1L3MBTL1SRD5A2ATM | |
| Benzophenone SCHEMBL28491203 | 0.94 | ALDH1A1 (1.00) | ALDH1A1TDP1L3MBTL1SRD5A2ATM | |
| Benzophenone SCHEMBL30536983 | 0.94 | ALDH1A1 (1.00) | ALDH1A1TDP1L3MBTL1SRD5A2ATM | |
| Benzophenone SCHEMBL6061130 | 0.94 | ALDH1A1 (1.00) | ALDH1A1TDP1L3MBTL1SRD5A2ATM | |
| Benzophenone SCHEMBL6678679 | 0.91 | ALDH1A1 (0.82) | ALDH1A1TDP1L3MBTL1SRD5A2ATM | |
| Benzophenone SCHEMBL28888896 | 0.91 | ALDH1A1 (0.82) | ALDH1A1TDP1L3MBTL1SRD5A2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113473971-B | Pharmaceutical formulations | 詹森药业有限公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-3810609-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-12 | — | — | EP | disclosed |
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-07 | — | — | US | disclosed |
| US-20230374329-A1 | Copper Oxide Ink and Method for Producing Conductive Substrate Using Same, Product Containing Coating Film and Method for Producing Product Using Same, Method for Producing Product with Conductive Pattern, and Product with Conductive Pattern | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-11-23 | — | — | US | disclosed |
| EP-3807266-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-25 | — | — | EP | disclosed |
| US-20230310413-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-05 | — | — | US | disclosed |
| US-11760895-B2 | Copper oxide ink and method for producing conductive substrate using same, product containing coating film and method for producing product using same, method for producing product with conductive pattern, and product with conductive pattern | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-09-19 | — | — | US | disclosed |
| EP-3922451-B1 | COPPER OXIDE INK AND METHOD FOR PRODUCING CONDUCTIVE SUBSTRATE USING SAME, PRODUCT CONTAINING COATING FILM AND METHOD FOR PRODUCING PRODUCT USING SAME, METHOD FOR PRODUCING PRODUCT WITH CONDUCTIVE PATTERN, AND PRODUCT WITH CONDUCTIVE PATTERN | ASAHI CHEMICAL IND (JP) | 2023-06-28 | — | — | EP | disclosed |
| EP-4199911-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | JANSSEN Pharmaceutica NV (BE) | 2023-06-28 | — | — | EP | disclosed |
| EP-4188930-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-6992138-B2 | Polyurethane polymer | KANEKA CORPORATION (JP) | 2006-01-31 | — | — | US | disclosed |
| US-20060004171-A1 | Process for producing vinyl polymer having alkenyl group at end, vinyl polymer, and curable composition | TSUJI RYOTARO | 2006-01-05 | — | — | US | disclosed |
| US-20040249026-A1 | Curable composition | KANEKA CORPORATION (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040236020-A1 | Block copolymer | KANEKA CORPORATION (JP) | 2004-11-25 | — | — | US | disclosed |
| US-20040171765-A1 | Polyurethane polymer | KANEKA CORPORATION (JP) | 2004-09-02 | — | — | US | disclosed |
| EP-1447422-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2004-08-18 | — | — | EP | disclosed |
| US-20040106732-A1 | Thermoplastic resin composition and elastomer composition | KANEKA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
| US-20040097678-A1 | Process for producing vinyl polymer having alkenyl group at end vinyl polymer and curable composition | KANEKA CORPORATION (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1411070-A1 | BLOCK COPOLYMER | KANEKA CORPORATION (JP) | 2004-04-21 | — | — | EP | disclosed |
| EP-1375531-A1 | PROCESS FOR PRODUCING VINYL POLYMER HAVING ALKENYL GROUP AT END, VINYL POLYMER, AND CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | CYP11B2, SDHA, UGT2B7 | ALDH1A1 241/4885TDP1 4145/4885L3MBTL1 4701/4885 |
| US-20230310413-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | MALT1, MGAM, MGLL | ALDH1A1 2560/4885TDP1 1334/4885L3MBTL1 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.